 |
|
|
| |
Aesica, a leading supplier of active pharmaceutical ingredients and formulated products to the global pharmaceutical industry, today announces it has taken a key step in further expanding its international presence with the establishment of a US subsidiary, Aesica LLC, which is based in Saddle Brook, New Jersey. The subsidiary will be headed by Michael Staff, Vice President, Sales & Business Development, North America who was appointed in April 2008.
North America is already Aesica's largest market accounting for more than 45% of the company's overall business and including customers in large pharma, generics companies and biotechnology companies. The establishment of a US subsidiary will drive further expansion and is the latest significant step in a period of exceptional growth for Aesica with the acquisition of manufacturing sites from Merck Sharpe & Dohme and Abbott and the move into secondary manufacturing.
Dr. Robert Hardy, CEO of Aesica said: "The establishment of our US subsidiary highlights our commitment to building on our already solid base in the world's largest pharmaceutical market. Michael is a highly experienced executive and with the benefit of a full subsidiary organisation will ensure we are able to get even closer to our clients. Our growth over recent years provides many exciting opportunities for customers in North America in both custom synthesis and API manufacturing as well as formulated products and packaging."
Michael Staff, said: "Aesica LLC will be dedicated to providing the exceptional levels of customer service and responsiveness that are at the heart of Aesica's approach to business and that clients have come to expect. We innovate in our commercial relationships, finding new ways of working with our customers to make their businesses a success and delivering high quality products on time, every time."
<< volver |
|
|
|
|
|
 |
|
 |
